次世代抗体医薬品の世界市場レポート (2025年)

次世代抗体医薬品の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR15.8％で297億2,000万米ドルに成長します。予測期間における成長の原動力は、個別化医療に対する需要の高まり、医薬品パイプラインの拡大、医療に対する意識の高まり、研究協力の増加、高齢化人口の増加などが見込まれます。予測期間における主な動向としては、抗体薬物複合体の進歩、二重特異性抗体の技術進歩、次世代シーケンサーの統合、タンパク質工学の開発、遺伝子治療統合の進歩などが挙げられます。

個別化医療が重視されるようになり、次世代抗体医薬品市場の拡大が見込まれます。個別化医療は、より効果的で的を絞った治療を提供するために、患者の遺伝的、環境的、生活習慣的要因を考慮し、医療や治療アプローチを個々の患者に合わせるものです。この個別化医療へのシフトは、より正確な診断とオーダーメイドの治療計画を可能にするゲノム配列決定の進歩によって後押しされています。次世代抗体医薬品は、患者固有の遺伝的体質や疾患の特徴に合わせた治療法の開発を可能にし、有効性を高め、副作用を軽減することで、この傾向を支えています。例えば、2024年2月、個別化医療を推進する米国を拠点とする団体である個別化医療連合（Personalized Medicine Coalition）は、2023年に米国食品医薬品局（FDA）が希少疾患に対する16の新しい個別化治療を承認し、2022年の6から増加したと報告しました。このように、個別化医療の重視の高まりが次世代抗体医薬品市場を牽引しています。

次世代抗体医薬品市場の各社は、標的がん治療を改善し、治療効果を高め、全身毒性を最小限に抑えるため、抗体薬物複合体（ADC）などの革新的ソリューションの開発に注力しています。ADCは、リンカーを介してモノクローナル抗体と細胞毒性薬剤を結合させ、健常組織を温存しながら腫瘍細胞を特異的に標的とすることを可能にします。例えば、2024年1月、ドイツのバイオテクノロジー企業であるBioNTech SEは、中国の製薬会社であるDuality Biologics（Suzhou）Co. Ltd.と提携し、プラチナ製剤抵抗性卵巣がんの治療を目的としたADC候補薬BNT325/DB-1305について、米国FDAからファスト・トラック指定を受けた。このドラッグデリバリーは、デュアリティ・バイオ社のDITAC（Duality Immune Toxin Antibody Conjugates）プラットフォームを利用したもので、高活性の細胞毒性ペイロードとモノクローナル抗体を組み合わせ、がん細胞への正確な送達を保証します。BNT325/DB-1305は、健康な組織への害を最小限に抑えながら、がん細胞を選択的に標的とすることができるため、治療効果を高め、副作用を軽減する上で重要な利点となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場のマクロ経済シナリオ：金利・インフレ・地政学・貿易戦争・関税・コロナ禍と回復が市場に及ぼす影響を含む

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の次世代抗体医薬品市場：PESTEL分析（政治・社会・技術・環境・法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の次世代抗体医薬品市場：成長率分析
• 世界の次世代抗体医薬品の市場規模・成長率：実績値、2019～2024年
• 世界の次世代抗体医薬品の市場規模・成長率：予測値、2024～2029年、2034年
• 世界の次世代抗体医薬品市場：総有効市場（TAM）

第6章 市場セグメンテーション

• 世界の次世代抗体医薬品市場：製品種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• モノクローナル抗体
• 二重特異性抗体
• 抗体薬物複合体
• その他の種類
• 世界の次世代抗体医薬品市場：作用機序別、実績値・予測値、2019～2024年、2024～2029年、2034年
• チェックポイント阻害剤
• 免疫調節薬
• 受容体遮断薬
• 標的細胞傷害剤
• 中和抗体
• 世界の次世代抗体医薬品市場：送達方法別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 静脈内（IV）投与
• 皮下投与
• 筋肉内投与
• 経口製剤
• 経皮送達システム
• 世界の次世代抗体医薬品市場：用途別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 腫瘍
• 自己免疫疾患
• 感染症
• その他の用途
• 世界の次世代抗体医薬品市場：エンドユーザー別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 病院
• 研究機関
• 専門クリニック
• その他のエンドユーザー
• 世界の次世代抗体医薬品市場（モノクローナル抗体）：製品種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• ヒトモノクローナル抗体
• マウスモノクローナル抗体
• ヒト化モノクローナル抗体
• キメラモノクローナル抗体
• 世界の次世代抗体医薬品市場（二重特異性抗体）：製品種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• チェックポイント阻害剤ベースの二重特異性抗体
• サイトカイン調節用の二重特異性抗体
• 半減期延長技術を用いた二重特異性抗体
• T細胞エンゲージャー
• 世界の次世代抗体医薬品市場（抗体薬物複合体）：製品種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 切断性リンカー抗体薬物複合体
• 非切断性リンカー抗体薬物複合体
• 部位特異的結合抗体薬物複合体
• 世界の次世代抗体医薬品市場（その他の種類）：製品種類別、実績値・予測値、2019～2024年、2024～2029年、2034年
• テクリスタマブ
• モスネツズマブ

第7章 地域別・国別の分析

• 世界の次世代抗体医薬品市場：地域別、実績値・予測値、2019～2024年、2024～2029年、2034年
• 世界の次世代抗体医薬品市場：国別、実績値・予測値、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 次世代抗体医薬品市場：競合情勢
• 次世代抗体医薬品市場：企業プロファイル
  • Actinium Pharmaceuticals Inc.（概要、製品・サービス、戦略、財務分析）
  • Pfizer Inc.（概要、製品・サービス、戦略、財務分析）
  • F. Hoffmann-La Roche Ltd.（概要、製品・サービス、戦略、財務分析）
  • Bristol-Myers Squibb Company（概要、製品・サービス、戦略、財務分析）
  • AstraZeneca plc（概要、製品・サービス、戦略、財務分析）

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Kyowa Hakko Kirin Co. Ltd.
• Samsung Biologics Co. Ltd.
• WuXi Biologics Inc.
• Akeso Inc.
• Xencor Inc.
• ImmunoGen Inc.
• Philogen S.p.A.
• Telix Pharmaceuticals Limited

第32章 世界市場：競合ベンチマーキング・ダッシュボード

第33章 主要な企業合併・買収 (M&A)

第34章 最近の市場動向

第35章 市場の潜在力の高い国・部門と戦略

• 次世代抗体医薬品市場：最新機会を提供する国（2029年）
• 次世代抗体医薬品市場：最新機会を提供する部門（2029年）
• 次世代抗体医薬品市場：成長戦略（2029年）
  • 市場動向に基づく戦略
  • 競争戦略

第36章 付録

Next-generation antibody drugs are advanced therapeutic antibodies developed to target specific antigens with greater precision and efficacy, often incorporating innovative technologies such as bispecific antibodies or antibody-drug conjugates. These drugs aim to enhance disease treatment outcomes by improving targeting abilities and reducing side effects.

The main product types of next-generation antibody drugs include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are identical copies of a single antibody, created by cloning a unique immune cell, and are used to treat various conditions such as cancer and autoimmune disorders. Their mechanisms of action include checkpoint inhibitors, immune modulators, receptor blockers, targeted cytotoxic agents, and neutralizing antibodies. Delivery methods for these drugs include intravenous (IV), subcutaneous, intramuscular administration, oral formulations, and transdermal delivery systems. They are applied in oncology, autoimmune diseases, infectious diseases, and other areas, and are used by hospitals, research institutes, specialty clinics, and other healthcare providers.

The next generation antibody drug market research report is one of a series of new reports from The Business Research Company that provides next generation antibody drug market statistics, including the next generation antibody drug industry's global market size, regional shares, competitors with the next generation antibody drug market share, detailed next-generation antibody drug market segments, market trends and opportunities, and any further data you may need to thrive in the next generation antibody drug market. This next generation antibody drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The next generation antibody drug market size has grown rapidly in recent years. It will grow from $14.26 billion in 2024 to $16.54 billion in 2025 at a compound annual growth rate (CAGR) of 16.0%. The growth during the historic period can be attributed to the increasing demand for targeted therapies, rising cancer prevalence, growing adoption of immuno-oncology therapies, heightened focus on autoimmune diseases, and expanding regulatory support.

The next generation antibody drug market size is expected to see rapid growth in the next few years. It will grow to $29.72 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period is expected to be driven by rising demand for personalized medicine, expanding drug pipelines, increasing healthcare awareness, more research collaborations, and a growing aging population. Major trends in the forecast period include advancements in antibody-drug conjugates, technological progress in bispecific antibodies, integration of next-generation sequencing, developments in protein engineering, and advancements in gene therapy integration.

The growing emphasis on personalized medicine is anticipated to drive the expansion of the next-generation antibody-drug market. Personalized medicine tailors healthcare and treatment approaches to individual patients, considering their genetic, environmental, and lifestyle factors to provide more effective and targeted therapies. This shift toward personalized medicine is fueled by advancements in genomic sequencing, which allow for more accurate diagnoses and customized treatment plans. Next-generation antibody drugs support this trend by enabling the development of therapies tailored to a patient's unique genetic makeup and disease characteristics, enhancing efficacy and reducing side effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization promoting personalized medicine, reported that in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases, up from 6 in 2022. Thus, the growing emphasis on personalized medicine is driving the next-generation antibody drug market.

Companies in the next-generation antibody drug market are focusing on developing innovative solutions, such as antibody-drug conjugates (ADCs), to improve targeted cancer therapies, enhance treatment efficacy, and minimize systemic toxicity. ADCs combine a monoclonal antibody with a cytotoxic drug via a linker, allowing the drug to specifically target tumor cells while sparing healthy tissue. For instance, in January 2024, BioNTech SE, a Germany-based biotechnology firm, partnered with Duality Biologics (Suzhou) Co. Ltd., a Chinese pharmaceutical company, to receive a Fast Track designation from the U.S. FDA for their ADC candidate, BNT325/DB-1305, intended to treat platinum-resistant ovarian cancer. This drug utilizes DualityBio's DITAC (Duality Immune Toxin Antibody Conjugates) platform, which pairs a highly potent cytotoxic payload with a monoclonal antibody, ensuring precise delivery to cancer cells. The ability of BNT325/DB-1305 to selectively target cancer cells while minimizing harm to healthy tissue is a key advantage in enhancing treatment outcomes and reducing side effects.

In March 2024, Johnson & Johnson, a U.S.-based pharmaceutical company, acquired Ambrx Biopharma for an undisclosed sum. Through this acquisition, Johnson & Johnson aims to enhance its oncology portfolio by developing advanced, targeted antibody-drug conjugates that improve outcomes and minimize side effects for patients with hard-to-treat cancers. Ambrx Biopharma is dedicated to advancing the development of next-generation antibody-drug conjugates.

Major players in the next generation antibody drug market are Actinium Pharmaceuticals Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Akeso Inc., Xencor Inc., ImmunoGen Inc., Philogen S.p.A., Telix Pharmaceuticals Limited.

North America was the largest region in the next generation antibody drug market in 2024. The regions covered in next generation antibody drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the next generation antibody drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next generation antibody drug market consists of sales of engineered monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific antibodies, and related biologic therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next Generation Antibody Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next generation antibody drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next generation antibody drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The next generation antibody drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Monoclonal Antibodies; Bispecific Antibodies; Antibody-Drug Conjugates; Other Types
• 2) By Mechanism Of Action: Checkpoint Inhibitors; Immune Modulators; Receptor Blockers; Targeted Cytotoxic Agents; Neutralizing Antibodies
• 3) By Delivery Method: Intravenous (IV) Administration; Subcutaneous Administration; Intramuscular Administration; Oral Formulations; Transdermal Delivery Systems
• 4) By Application: Oncology; Autoimmune Diseases; Infectious Diseases; Other Applications
• 5) By End User: Hospitals; Research Institutes; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Monoclonal Antibodies: Human Monoclonal Antibodies; Murine Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies
• 2) By Bispecific Antibodies: Checkpoint Inhibitor-Based Bispecifics; Bispecific Antibodies For Cytokine Modulation; Bispecific Antibodies With Extended Half-Life Technologies
• 3) By Antibody-Drug Conjugates: Cleavable Linker Antibody-Drug Conjugates; Non-Cleavable Linker Antibody-Drug Conjugates; Site-Specific Conjugated Antibody-Drug Conjugates
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb Company; AstraZeneca plc; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Next Generation Antibody Drug Market Characteristics

3. Next Generation Antibody Drug Market Trends And Strategies

4. Next Generation Antibody Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Next Generation Antibody Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Next Generation Antibody Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Next Generation Antibody Drug Market Growth Rate Analysis
• 5.4. Global Next Generation Antibody Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Next Generation Antibody Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Next Generation Antibody Drug Total Addressable Market (TAM)

6. Next Generation Antibody Drug Market Segmentation

• 6.1. Global Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Bispecific Antibodies
• Antibody-Drug Conjugates
• Other Types
• 6.2. Global Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitors
• Immune Modulators
• Receptor Blockers
• Targeted Cytotoxic Agents
• Neutralizing Antibodies
• 6.3. Global Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV) Administration
• Subcutaneous Administration
• Intramuscular Administration
• Oral Formulations
• Transdermal Delivery Systems
• 6.4. Global Next Generation Antibody Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Other Applications
• 6.5. Global Next Generation Antibody Drug Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Research Institutes
• Specialty Clinics
• Other End Users
• 6.6. Global Next Generation Antibody Drug Market, Sub-Segmentation Of Monoclonal Antibodies, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Monoclonal Antibodies
• Murine Monoclonal Antibodies
• Humanized Monoclonal Antibodies
• Chimeric Monoclonal Antibodies
• 6.7. Global Next Generation Antibody Drug Market, Sub-Segmentation Of Bispecific Antibodies, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitor-Based Bispecifics
• Bispecific Antibodies For Cytokine Modulation
• Bispecific Antibodies With Extended Half-Life Technologies
• T-Cell Engagers
• 6.8. Global Next Generation Antibody Drug Market, Sub-Segmentation Of Antibody-Drug Conjugates, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cleavable Linker Antibody-Drug Conjugates
• Non-Cleavable Linker Antibody-Drug Conjugates
• Site-Specific Conjugated Antibody-Drug Conjugates
• 6.9. Global Next Generation Antibody Drug Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Teclistamab
• Mosunetuzumab

7. Next Generation Antibody Drug Market Regional And Country Analysis

• 7.1. Global Next Generation Antibody Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Next Generation Antibody Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next Generation Antibody Drug Market

• 8.1. Asia-Pacific Next Generation Antibody Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next Generation Antibody Drug Market

• 9.1. China Next Generation Antibody Drug Market Overview
• 9.2. China Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next Generation Antibody Drug Market

• 10.1. India Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next Generation Antibody Drug Market

• 11.1. Japan Next Generation Antibody Drug Market Overview
• 11.2. Japan Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next Generation Antibody Drug Market

• 12.1. Australia Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next Generation Antibody Drug Market

• 13.1. Indonesia Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next Generation Antibody Drug Market

• 14.1. South Korea Next Generation Antibody Drug Market Overview
• 14.2. South Korea Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next Generation Antibody Drug Market

• 15.1. Western Europe Next Generation Antibody Drug Market Overview
• 15.2. Western Europe Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next Generation Antibody Drug Market

• 16.1. UK Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next Generation Antibody Drug Market

• 17.1. Germany Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next Generation Antibody Drug Market

• 18.1. France Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next Generation Antibody Drug Market

• 19.1. Italy Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next Generation Antibody Drug Market

• 20.1. Spain Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next Generation Antibody Drug Market

• 21.1. Eastern Europe Next Generation Antibody Drug Market Overview
• 21.2. Eastern Europe Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next Generation Antibody Drug Market

• 22.1. Russia Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next Generation Antibody Drug Market

• 23.1. North America Next Generation Antibody Drug Market Overview
• 23.2. North America Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next Generation Antibody Drug Market

• 24.1. USA Next Generation Antibody Drug Market Overview
• 24.2. USA Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next Generation Antibody Drug Market

• 25.1. Canada Next Generation Antibody Drug Market Overview
• 25.2. Canada Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next Generation Antibody Drug Market

• 26.1. South America Next Generation Antibody Drug Market Overview
• 26.2. South America Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next Generation Antibody Drug Market

• 27.1. Brazil Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next Generation Antibody Drug Market

• 28.1. Middle East Next Generation Antibody Drug Market Overview
• 28.2. Middle East Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next Generation Antibody Drug Market

• 29.1. Africa Next Generation Antibody Drug Market Overview
• 29.2. Africa Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next Generation Antibody Drug Market Competitive Landscape And Company Profiles

• 30.1. Next Generation Antibody Drug Market Competitive Landscape
• 30.2. Next Generation Antibody Drug Market Company Profiles
  • 30.2.1. Actinium Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Next Generation Antibody Drug Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Gilead Sciences Inc.
• 31.4. Amgen Inc.
• 31.5. Boehringer Ingelheim International GmbH
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. Biogen Inc.
• 31.8. Kyowa Hakko Kirin Co. Ltd.
• 31.9. Samsung Biologics Co. Ltd.
• 31.10. WuXi Biologics Inc.
• 31.11. Akeso Inc.
• 31.12. Xencor Inc.
• 31.13. ImmunoGen Inc.
• 31.14. Philogen S.p.A.
• 31.15. Telix Pharmaceuticals Limited

32. Global Next Generation Antibody Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next Generation Antibody Drug Market

34. Recent Developments In The Next Generation Antibody Drug Market

35. Next Generation Antibody Drug Market High Potential Countries, Segments and Strategies

• 35.1 Next Generation Antibody Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Next Generation Antibody Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Next Generation Antibody Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer